Twelve chronic hepatitis C patients ranging in age from 3 to 21 years ( mean , 13.9 5.1 years ) who received pegylated interferon -2 b and ribavirin combination therapy were randomized to either the control group ( n = 6 ) or EPA group ( n = 6 ) .
